Welcome to the international HTA database

Showing [16734 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2021	National Institute for Health and Care Excellence (NICE)	Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 725
2021	NIHR Health Technology Assessment programme	The ACUTE (Ambulance CPAP: Use, Treatment effect and Economics) feasibility study: a pilot randomised controlled trial of prehospital CPAP for acute respiratory failure
2021	Swiss Federal Office of Public Health (FOPH)	Corneal collagen crosslinking for the treatment of progressive keratoconus
2021	Institute for Clinical and Economic Review (ICER)	Anti b-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma
2021	National Institute for Health and Care Excellence (NICE)	Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 726
2021	Swiss Federal Office of Public Health (FOPH)	Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis
2021	Institute for Clinical and Economic Review (ICER)	Belimumab and voclosporin for lupus nephritis: effectiveness and value
2021	National Institute for Health and Care Excellence (NICE)	Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 727
2021	Institute for Clinical and Economic Review (ICER)	Treatments for anemia in chronic kidney disease: effectiveness and value
2021	National Institute for Health and Care Excellence (NICE)	Midostaurin for treating advanced systemic mastocytosis. NICE technology appraisal guidance 728
2021	Swiss Federal Office of Public Health (FOPH)	Medical cannabis for treating various symptoms in Switzerland
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Fall risk assessment in oncology patients
2021	Institute for Clinical and Economic Review (ICER)	Bempedoic acid and inclisiran for patients with heterozygous familial hypercholesterolemia and for secondary prevention of ASCVD: effectiveness and value
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Delaying surgery for patients recovering from COVID-19. A rapid review comissioned by RACS
2021	Canadian Agency for Drugs and Technologies in Health (CADTH)	Phosphodiesterase type-5 inhibitors for the treatment of secondary Raynaud's phenomenon and digital ulcers
2021	National Institute for Health and Care Excellence (NICE)	Sapropterin for treating hyperphenylalaninaemia in phenylketonuria. NICE technology appraisal guidance 729
2021	Swiss Federal Office of Public Health (FOPH)	Palbociclib (Ibrance®), ribociclib (Kisqali®) and abemaciclib (Verzenios®) for the treatment of hormone receptor (HR)-positive, human epidermal growth factor (HER2)-negative advanced breast cancer
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Effects of masks on the health of schoolchildren
2021	National Institute for Health and Care Excellence (NICE)	Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal). NICE technology appraisal guidance 730
2021	Ontario Health	Nonthermal endovenous treatments for varicose veins
2021	Swiss Federal Office of Public Health (FOPH)	Subacromial decompression as a primary/isolated intervention to treat subacromial pain
2021	NIHR Health Technology Assessment programme	Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis
2021	National Institute for Health and Care Excellence (NICE)	Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal). NICE technology appraisal guidance 731
2021	Ontario Health	Prostatic artery embolization for benign prostatic hyperplasia
2021	Swiss Federal Office of Public Health (FOPH)	The treatment of hypercholesterolaemia and mixed/combined hyperlipidaemia with ezetimibe-containing medicines
2021	Belgian Health Care Knowledge Centre (KCE)	Long COVID: Pathophysiology – epidemiology and patient needs
2021	National Institute for Health and Care Excellence (NICE)	Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal). NICE technology appraisal guidance 732
2021	Ontario Health	Skin substitutes for adults with diabetic foot ulcers and venous leg ulcers
2021	National Institute for Health and Care Excellence (NICE)	Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. NICE technology appraisal guidance 733
2021	Ontario Health	Repetitive Transcranial Magnetic Stimulation for People With Treatment-Resistant Depression
2021	National Institute for Health and Care Excellence (NICE)	Secukinumab for treating moderate to severe plaque psoriasis in children and young people. NICE technology appraisal guidance 734
2021	Ontario Health	Pigmented lesion assay for suspected melanoma lesions
2021	National Institute for Health and Care Excellence (NICE)	Tofacitinib for treating juvenile idiopathic arthritis. NICE technology appraisal guidance 735
2021	Ontario Health	Proton Beam Therapy for Cancer in Children and Adults: A Health Technology Assessment
2021	National Institute for Health and Care Excellence (NICE)	Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy. NICE technology appraisal guidance 736
2021	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: mandatory vaccination
2021	Health Technology Wales (HTW)	Handheld single lead electrocardiogram devices to detect atrial fibrillation in older adults and those with intermittent episodes
2021	National Institute for Health and Care Excellence (NICE)	Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer. NICE technology appraisal guidance 737
2021	Ontario Health	Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure
2021	Health Technology Wales (HTW)	Point-of-care ultrasound to diagnose gallstone disease
2021	National Institute for Health and Care Excellence (NICE)	Berotralstat for preventing recurrent attacks of hereditary angioedema. NICE technology appraisal guidance 738
2021	Ontario Health	Vaginal pessaries for pelvic organ prolapse and stress urinary incontinence
2021	Scottish Medicines Consortium (SMC)	Secukinumab for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)
2021	National Institute for Health and Care Excellence (NICE)	Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable. NICE technology appraisal guidance 739
2021	Scottish Medicines Consortium (SMC)	Brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL)
2021	National Institute for Health and Care Excellence (NICE)	Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer. NICE technology appraisal guidance 740
2021	Scottish Medicines Consortium (SMC)	Melatonin (Slenyto) for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
2021	Health Technology Wales (HTW)	Natriuretic peptides to rule-in and rule-out a diagnosis of acute heart failure in adults in the emergency department setting
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	National spending and uptake of mobile radiology services in aged care facilities: an opportunity to improve access remains
2021	National Institute for Health and Care Excellence (NICE)	Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 741
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Ambulatory antibiotic prophylaxis for skin procedures
2021	National Institute for Health and Care Excellence (NICE)	Selpercatinib for treating advanced thyroid cancer with RET alterations. NICE technology appraisal guidance 742
2020	Technology Assessment at SickKids (TASK)	Microcosting of whole genome sequencing (WGS) of trios in heterogeneous pediatric cardiac population
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: prophylactic use of hydroxychloroquine (HCQ)
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: treatment with hydroxychloroquine (HCQ)
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: infectivity of patients who have recovered from disease
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Cytokine adsorption for treatment of COVID-19 disease
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: decontamination and reprocessing of personal protective equipment (PPE)
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Transmission of respiratory infections via showers
2020	NIHR Health Technology Assessment programme	Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Remdesivir for treatment of COVID-19 disease
2020	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	Treatment of depression with transcranial magnetic stimulation using an H-coil (dTMS)
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: sedation-ventilation liberation of COVID+ patients
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: surgical masks and filtering face piece respirators (FFR) for health care providers
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: point-of-care (POC) testing
2020	Adelaide Health Technology Assessment (AHTA)	Genetic testing for diagnosis of inheritable cardiac rhythm disorders
2020	NIHR Health Technology Assessment programme	Best-practice prevention alone or with conventional or biological caries management for 3- to 7-year-olds: the FiCTION three-arm RCT
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: antibiotic management in ambulatory patients
2020	Adelaide Health Technology Assessment (AHTA)	Detection of aquaporin-4 (AQP4) and myelin oligodendrocyte glycoprotein antibody (MOG) antibodies for diagnosis of neuromyelitis optica (NMO) and myelin oligodendrocyte glycoprotein antibody-related demyelination (MARD)
2020	NIHR Health Technology Assessment programme	Total versus partial knee replacement in patients with medial compartment knee osteoarthritis: the TOPKAT RCT
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: temperature screening for healthcare personnel
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: criteria for discharging patients from inpatient care
2020	Norwegian Institute of Public Health (NIPH)	Safety, clinical effectiveness, predictive accuracy and cost effectiveness of blood based tests for women with suspected preeclampsia: a health technology assessment
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: high flow nasal cannula (HFNC)/non-invasive positive pressure ventilation (NIPPV) indications
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: proning considerations for patients on HFNC or BIPAP
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: criteria for advising home care patients to return to the hospital
2020	NIHR Health Services and Delivery Research programme	Stroke Sentinel Audit Programme: Investigating and Evaluating Stroke Therapy (SSNAPIEST)
2020	Norwegian Institute of Public Health (NIPH)	Intracoronary lithotripsy for the treatment of coronary artery disease: a health technology assessment
2020	Penn Medicine Center for Evidence-based Practice (CEP)	COVID-19: surge triage for suspected influenza-like illness
2020	NIHR Health Services and Delivery Research programme	An evaluation of a multifaceted intervention to reduce antimicrobial prescribing in care home residents [REducing Antimicrobials in Care Homes (REACH)]: a non-randomised feasibility study and process evaluation
2020	Norwegian Institute of Public Health (NIPH)	Disease modifying drugs for treatment of primary progressive multiple sclerosis: A health technology assessment
2020	NIHR Health Services and Delivery Research programme	UK Study of tendon Achilles Rehabilitation multicentre randomised clinical trial (UK STAR)
2020	Scottish Health Technologies Group (SHTG)	The Scottish asynchronous digital dermatology appointment service (DDAS)
2020	Health Information and Quality Authority (HIQA)	Evidence summary of the immune response following infection with SARS-CoV-2 or other human coronaviruses
2020	NIHR Health Technology Assessment programme	Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation
2020	Health Information and Quality Authority (HIQA)	Factors influencing, and measures to improve, vaccination uptake: rapid evidence summary
2020	Canadian Agency for Drugs and Technologies in Health (CADTH)	Condition-level review on tuberculosis: repository of evidence and resources
2020	Health Information and Quality Authority (HIQA)	Face mask use by healthy people in the community to reduce SARS-CoV-2 transmission – protocol for rapid evidence update
2020	NIHR Health Services and Delivery Research programme	IMPlementation of A Relatives Toolkit (IMPART study): examining the critical success factors, barriers and facilitators to implementation of an online supported self-management intervention in the NHS
2020	NIHR Health Technology Assessment programme	Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
2020	Health Information and Quality Authority (HIQA)	Categorisation of ‘extremely medically vulnerable’ groups who may be at risk of severe illness from COVID-19: evidence review
2020	NIHR Health Technology Assessment programme	Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation
2020	Health Information and Quality Authority (HIQA)	Analysis of spatial patterns of respiratory mortality in the HSE Mid-West region
2020	NIHR Health Technology Assessment programme	Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation
2020	Health Information and Quality Authority (HIQA)	Evidence summary on activities or settings associated with a higher risk of SARS-CoV-2 transmission
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Proton and carbon ion therapy - an update on indications
2020	NIHR Health Technology Assessment programme	Oral splints for patients with temporomandibular disorders or bruxism: a systematic review and economic evaluation
2020	NIHR Health Technology Assessment programme	Interventions to reduce the risk of surgically transmitted Creutzfeldt–Jakob disease: a cost-effective modelling review
2020	Malaysian Health Technology Assessment (MaHTAS)	Pre-dialysis education programme (PDEP)
2020	Malaysian Health Technology Assessment (MaHTAS)	Diagnostic approaches to solitary pulmonary nodule (SPN)